- Home
- AWH vs WINT Comparison
AWH vs WINT Comparison
Compare AWH & WINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AWH
- WINT
- Stock Information
- Founded
- AWH 1993
- WINT 1992
- Country
- AWH United States
- WINT United States
- Employees
- AWH N/A
- WINT N/A
- Industry
- AWH Medical/Dental Instruments
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AWH Health Care
- WINT Health Care
- Exchange
- AWH Nasdaq
- WINT Nasdaq
- Market Cap
- AWH 1.6M
- WINT 1.5M
- IPO Year
- AWH N/A
- WINT 1995
- Fundamental
- Price
- AWH $0.11
- WINT $1.56
- Analyst Decision
- AWH Buy
- WINT Hold
- Analyst Count
- AWH 2
- WINT 1
- Target Price
- AWH $4.40
- WINT $350.00
- AVG Volume (30 Days)
- AWH 12.9M
- WINT 8.2M
- Earning Date
- AWH 03-27-2025
- WINT 04-15-2025
- Dividend Yield
- AWH N/A
- WINT N/A
- EPS Growth
- AWH N/A
- WINT N/A
- EPS
- AWH N/A
- WINT N/A
- Revenue
- AWH $9,182,000.00
- WINT N/A
- Revenue This Year
- AWH $11.87
- WINT N/A
- Revenue Next Year
- AWH $79.10
- WINT N/A
- P/E Ratio
- AWH N/A
- WINT N/A
- Revenue Growth
- AWH 0.31
- WINT N/A
- 52 Week Low
- AWH $0.08
- WINT $1.45
- 52 Week High
- AWH $3.63
- WINT $737.50
- Technical
- Relative Strength Index (RSI)
- AWH 29.83
- WINT 28.70
- Support Level
- AWH $0.12
- WINT $1.64
- Resistance Level
- AWH $0.36
- WINT $2.17
- Average True Range (ATR)
- AWH 0.03
- WINT 0.34
- MACD
- AWH 0.01
- WINT 0.24
- Stochastic Oscillator
- AWH 9.00
- WINT 5.42
About AWH Aspira Women's Health Inc.
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its products include OvaSuite which is a portfolio of blood tests that applies proprietary algorithms incorporating patient features; OvaWatch intended for use in assessing the risk of ovarian cancer for women with adnexal masses; and Ova1Plus is a portfolio of blood tests, Ova1Plus is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery.
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.